SCHEMBL25722367

SCHEMBL25722367

COc1cc(-n2c(=O)ccc3cccnc32)cc(OC)c1OC

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HPGD P15428 1/20 0.44
POLB P06746 2/20 0.43
PDE4B Q07343 3/20 0.42
PDE4D Q08499 1/20 0.42
SLC22A12 Q96S37 2/20 0.42
SYK P43405 1/20 0.41
PDGFRB P09619 2/20 0.40
MAP3K11 Q16584 1/20 0.40
PDGFRA P16234 1/20 0.40
ACVR1 Q04771 1/20 0.40
NPC1 O15118 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPT P10636 1/20 0.39
PTAFR P25105 1/20 0.39
ACHE P22303 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25723282 0.93 PDE4B (0.40) MEN1KMT2AHPGDPOLBPDE4B
SCHEMBL10678879 0.82 PDE4B (0.43) MEN1KMT2AHPGDPOLBPDE4B
SCHEMBL25722366 0.80 ALDH1A1 (0.50) MEN1KMT2APDE4BSMN1; SMN2MAPT
SCHEMBL11056945 0.75 CDK4 (0.51) PDE4BPDE4D
Hydrochloric Acid SCHEMBL10722765 0.74 CDK4 (0.50) PDE4BPDE4D
SCHEMBL27250846 0.72 PDE4B (0.46) MEN1KMT2AHPGDPOLBPDE4B
SCHEMBL9615234 0.72 CDK4 (0.45) MAPT
SCHEMBL29407807 0.72 HPGD (0.48) MEN1KMT2AHPGDPDE4BPDE4D
SCHEMBL27252044 0.69 POLB (0.41) HPGDPOLBPDE4BNPC1MAPT
SCHEMBL30826020 0.69 POLB (0.41) HPGDPOLBPDE4BNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230202980-A1 N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2023-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202980-A1 N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer SALL4, GLI2, GLI1 MEN1 1716/4885KMT2A 680/4885HPGD 2751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.